Chloroquine (HY-17589A), PGC-1-inhibitor (HY-101491), C75 (HY-12364), withaferin A (HY-N2065), and ferrostatin-1 (HY-100579) were purchased from MedChemExpress
NAD+ biosynthesis, aging, and disease
It participates in over 500 enzymatic reactions and is essential for energy production, DNA repair, and cellular signaling
Boston University Office of Research

MOTS-c Reconstitution Math MOTS-c - common doses at common vial sizes Vial Size 5 mg BAC Water 1.0 mL Concentration 5 mg/mL 5 mg Dose 1.0 mL (100 units) 2.5 mg Dose 0.50 mL (50 units) 1 mg Dose 0.20 mL (20 units) 200 mcg Dose 0.04 mL (4 units) Vial Size 5 mg BAC Water 2.0 mL Concentration 2.5 mg/mL 5 mg Dose 2.0 mL (200 units*) 2.5 mg Dose 1.0 mL (100 units) 1 mg Dose 0.40 mL (40 units) 200 mcg Dose 0.08 mL (8 units) Vial Size 10 mg BAC Water 1.0 mL Concentration 10 mg/mL 5 mg Dose 0.50 mL (50 units) 2.5 mg Dose 0.25 mL (25 units) 1 mg Dose 0.10 mL (10 units) 200 mcg Dose 0.02 mL (2 units) Vial Size 10 mg BAC Water 2.0 mL Concentration 5 mg/mL 5 mg Dose 1.0 mL (100 units) 2.5 mg Dose 0.50 mL (50 units) 1 mg Dose 0.20 mL (20 units) 200 mcg Dose 0.04 mL (4 units) Vial Size 10 mg BAC Water 3.0 mL Concentration 3.33 mg/mL 5 mg Dose 1.50 mL (150 units*) 2.5 mg Dose 0.75 mL (75 units) 1 mg Dose 0.30 mL (30 units) 200 mcg Dose 0.06 mL (6 units) * Volumes above 100 units exceed a standard 1 mL insulin syringe

Comparative GHRH analogue pharmacology With DAC versus Without DAC Studies systematically comparing CJC-1295 Without DAC and CJC-1295 With DAC characterise the consequences of pharmacokinetic profile on GH secretion pattern the transient pulsatile GH release produced by Mod-GRF 1-29 versus the sustained tonic GH elevation produced by the long-acting DAC variant